Tumor immunization of BMT recipients increases antitumor cytolytic activity and induces limited alloreactivity compared to immune C3H.SW controls.
Three months (A) or 1 month (B, C) after BMT, C3H.SW→ B6 recipients were immunized twice with irradiated 205IL-2/TK cells (205-immune) or irradiated C1498 leukemia cells (C1498-immune) at a 1-week interval. Control C3H.SW donors were also immunized in an identical manner. Ten days after the 2nd vaccine, spleens were harvested, and spleen cells were stimulated for 4 days in vitro with irradiated 205 (A, B) or C1498 (C). A 51Cr-release assay was performed using targets specified in the legends. B6 CAB are C57BL/6 ConA lymphoblasts. A, B, and C represent independent experiments with different panels of targets; neither P815 nor Yac cells were used as targets in experiment C because other experiments had demonstrated little or no LAK or NK activity. Data shown are at an E:T ratio of 200:1, and each effector:target condition was performed in triplicate using splenocytes pooled from 2 or 3 mice.
